PREP lab

Our latest publication was accepted in the Journal of Medicinal Chemistry! We have shown earlier that a reference PREP inhibitor, KYP-2047, has good efficacy in various alpha-synuclein based Parkinson's disease models. However, KYP-2047 is good reference but non-patentable, and having very little possibilities for further drug development.

In this paper, we describe a family of completely novel structure and family of PREP inhibitors, that are equally effective to KYP-2047 in alpha-synuclein-based mouse models (having disease-modifying effect). Great collaboration between our medicinal chemistry and pharmacology teams - and more to come!

Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson’s Disease Prolyl oligopeptidase (PREP) is a widely distributed serine protease in the human body cleaving proline-containing peptides; however, recent studies suggest that its effects on pathogenic processes underlying neurodegeneration are derived from direct protein–protein interactions (PPIs) and not fro...

It’s on! PhD dissertation of M.Sc. Tony Eteläinen from PREP lab. Looking forward to interesting discussion with the opponent, Prof. Heikki Tanila from Itä-Suomen yliopisto - University of Eastern Finland (UEF)

Next Friday my 5th student from will defend PhD thesis, as M.Sc. Tony Eteläinen has his dissertation! Very excited to follow the discussion between Tony and his opponent, Prof. Heikki Tanila from University of Eastern Finland. Tony’s 3rd article for the thesis was just accepted (right in time) - more information about that will follow later this week 😉

Tony Eteläinen: The effect of prolyl oligopeptidase inhibition on protein aggregation and oxidative stress in the models of neurodegenerative diseases

Our team will be today and tomorrow at , presenting the NeuroPREP project. Come stop by if you are around!

NeuroPREP slows down the progression of neurodegenerative diseases | University of Helsinki Entirely novel compounds slow down or even halt the progression of Parkinson’s disease and Alzheimer's disease.

Although it has been quiet in PREP lab page, we have not been lazy. Check out our most recent paper at Neuropharmacology where we show that even if you reduce insoluble alpha-synuclein in mice (that should be toxic), it does not automatically protect the cells. Very nice work by Tony Eteläinen and Tommi Kilpeläinen!

ScienceDirect.com | Science, health and medical journals, full text articles and books. ScienceDirect is the world's leading source for scientific, technical, and medical research. Explore journals, books and articles.